INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 158,079 | $52.03 | 908,303 |
| Dec 30, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 158,079 | -- | -- |
| Dec 16, 2011 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 158,079 | -- | 158,079 |
| Feb 15, 2024 |
Director, Bd. Co-Chair, President & CSO
|
Director, Bd. Co-Chair, President & CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 172,723 | $399.66 | 925,209 |
| Feb 15, 2024 |
Director, Bd. Co-Chair, President & CSO
|
Director, Bd. Co-Chair, President & CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 172,723 | -- | -- |
| Dec 16, 2014 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 172,723 | -- | 172,723 |
| Aug 03, 2017 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Bona fide gift | 176,223 | -- | 176,223 |
| Aug 03, 2017 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Bona fide gift | 176,223 | -- | 155,406 |
| Jul 21, 2017 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Bona fide gift | 176,223 | -- | 323,777 |
| Jul 21, 2017 |
Director, President and CSO
|
Director, President and CSO | Form 4 | Bona fide gift | 176,223 | -- | 331,629 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.